drugset / Trial / NCT00327015

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00327015

Phase 3 Completed 1306 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone

Timeline

Start
2006-05
Primary completion
2007-11
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg Oral
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral
Subject SAXAGLIPTIN ANHYDROUS Small molecule 10 mg Oral
Background Pioglitazone Small molecule 15 mg Oral
Background Pioglitazone Small molecule 45 mg Oral